🔴 Novo Nordisk is trading 9.3% down today after experimental drug Ziltivekimab failed key cardiovascular trial

Novo Nordisk is trading 9.3% down at $46.82 due to significant company-specific news impacting its pipeline and legal standing:

• The company announced that its experimental IL-6 inhibitor, ziltivekimab, failed to meet its primary endpoint in the Phase 3 ZEUS trial, showing no reduction in major adverse cardiovascular events.
• Adding to the pressure, a U.S. District Court judge recently ruled that Novo Nordisk must face a shareholder securities fraud lawsuit regarding its CagriSema weight-loss drug.
• These setbacks occur amidst intensifying competition from Eli Lilly in the crucial GLP-1 market.